Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
Pfizer
on Tuesday reported fourth-quarter earnings King88bet Login and revenue that beat estimates as sales of the company's Covid products topped expectations and its broad cost-cutting usahas took hold.
Here's what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survei of analysts by LSEG:
Earnings per sharing: 63 cents adjusted versus. 46 cents expected
Revenue: $17.76 billion versus. $17.36 billion expected
Shares of Pfizer were down slightly on Tuesday.
The results cap off a critical King88bet Slot year for Pfizer, which has been pursuing broad biaya reductions as it recovers from the rapid decline of its Covid business and stok price over the last two years. The company said it is on trek to deliver overall net biaya savings of roughly $4.5 billion by the end of 2025 from its cost-cutting program.
Pfizer believes "our revenue volatility is largely in the past as Covid-related uncertainties have diminished," the company's CFO Dave Denton said on an earnings call on Tuesday. "Additionally, our biaya improvement programs have set the stage for ongoing margin expansion."
The company booked fourth-quarter net penghasilan of $410 million, or 7 cents per sharing. That compares with a net loss of $3.37 billion, or a loss of 60 cents per sharing, during the same period a year ago.
Excluding certain items, including restructuring King88bet Terpercaya charges and costs associated with intangible assets, the company posted earnings per sharing of 63 cents for the quarter.
Pfizer reported revenue of $17.76 billion for the fourth quarter, up 22% from the same period a year ago.
The fourth-quarter results are "unlikely to shock many investors, but we view another top- and bottom-line beat as positive for improving sentiment," BMO Capital Markets analyst Evan Seigerman said in a research catatan on Tuesday.
The company reiterated the full-year 2025 outlook it provided in December, forecasting sales of $61 billion to $64 billion, with a similar performnce from its Covid products as seen in 2024. Denton noted that changes to the Medicare program resulting from the Inflation Reduction Act will hurt sales by $1 billion, dampening growth by approximately 1.6% compared to 2024.
Stripping out one-time items, the company expects 2025 earnings to be in the kisaran of $2.80 to $3 a sharing.
But Wall Street is likely more concerned with Pfizer's long-term financial health and its drug pipeline. Investors are also watching to see whether Pfizer can win a slice of the meledak weight loss drug pasar with the once-daily version of its experimental obesity pill, danuglipron.
Pfizer appears to have dodged a proxy battle with activist investor Starboard Nilai, which has a roughly $1 billion stake in the pharmaceutical giant, for now. The deadline passed for nominating board members for this year.
Covid products hebat estimates
Pfizer's fourth-quarter beat was fueled in part by higher-than-expected permintaan for its Covid products.